AccuMetab™ Human CYP4F3 Enzyme, Catalytically Active with Cytochrome b5
CAT#: ITS-0426-YL70
Product Type: Recombinant Phase I Metabolizing Enzyme
Brand: AccuMetab
Development Stage: ADME
ADME Research Domain: Metabolism
Short Description
Enhanced human CYP4F3 for high-activity Phase I metabolism profiling.
Brand
AccuMetab
Development Stage
ADME
ADME Research Domain
Metabolism
Background
The inclusion of Cytochrome b5 significantly amplifies the lipid-hydroxylating efficiency of CYP4F3. This optimized system is an excellent tool for ADME researchers focused on the rapid clearance mapping of novel lipophilic drugs and endogenous inflammatory mediators.
Key Features
Cytochrome b5 supplemented for max catalytic turnover; Amplifies targeted lipid-hydroxylation efficiency; Gold-standard for anti-inflammatory lipid profiling; Available in multiple reductase ratios
Applications
Enhanced Drug Metabolism Studies, MetID, DDI
Research Areas
ADME; Drug-Drug Interactions (DDI)
Species
Human
Expression System
Recombinant enzymes prepared from E. coli and co-expressed with NADPH CYP-reductase.
Physical Form
Liquid
Size
0.5 nmol; 1 nmol; 4 nmol; 10 mg
Storage
-80°C
Storage Comment
When stored at -80°C, our product remains stable and retains full functional activity for up to 10 years.
Note
For bulk pricing or custom reagent inquiries, please contact us by email or phone. Products are shipped on ice via FedEx.
Restrictions
For Research Use Only (RUO). Not intended for diagnostic or therapeutic use.